Administering Hulio

  • Considerations
    • Dosing is similar to Humira—no new doses or dosing schedule to learn1,2
    • HULIO is intended for use under the guidance and supervision of a physician. A patient may self-inject HULIO or a caregiver may inject HULIO using either the HULIO pen or prefilled syringe if a physician determines that it is appropriate, after proper training in subcutaneous injection technique1
    • Prior to initiating HULIO and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection1
    • If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time1
    • There is no dosage form of HULIO that allows weight-based dosing for pediatric patients weighing less than 15 kg (or 33 lbs)1
    • Your patients may receive adalimumab-fkjp injection (either HULIO brand or unbranded)
  • Dosage Forms and Strengths
    Image of prefilled pen
    Prefilled Pen
    • Injection: 40 mg/0.8 mL in a single-dose pen
    • 2-step process with audible clicks and no buttons assures correct use, even for patients with disabilities
    • Does not need to be mixed or prepared
    • Medicine is injected automatically; patients never see the needle
    Image of prefilled syringe
    Prefilled Syringe
    • Injection: 40 mg/0.8 mL in a single-dose prefilled plastic syringe
    • Injection: 20 mg/0.4 mL in a single-dose prefilled plastic syringe

Hulio helps you get going and keep going

See how similar transitioning to HULIO will be for your current Humira patients.1,2
Click on the therapeutic area below to reveal recommended HULIO dosing for each indication.

  • Rheumatology
  • Dermatology
  • Gastroenterology
  • Opthamology
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Uveitis

ADULTS

MAINTENANCE


40 mg

every other week

Indication: HULIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HULIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).1

ADULTS

MAINTENANCE


40 mg

every other week

Indication: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.1

ADULTS

MAINTENANCE


40 mg

every other week

Indication: HULIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.1

CHILDREN ≥2 years
15 kg (33 lbs) to
<30 kg (66 lbs)
≥30 kg (66 lbs)

MAINTENANCE


20 mg

every other week

40 mg

every other week

There is no dosage form for HULIO that allows weight-based dosing for pediatric patients below 15 kg.

Adalimumab products have not been studied in patients with polyarticular juvenile idiopathic arthritis less than 2 years of age or in patients with a weight below 10 kg.

Indication: HULIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HULIO can be used alone or in combination with methotrexate.1

ADULTS

INDUCTION


Day 1:

80 mg

MAINTENANCE


Day 8:

40 mg

every other week

Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

Indication: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.1

  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Hidradenitis Suppurativa

ADULTS

MAINTENANCE


40 mg

every other week

Indication: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.1

ADULTS

INDUCTION


Day 1:

80 mg

MAINTENANCE


Day 8:

40 mg

every other week

Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

Indication: HULIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HULIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.1

ADULTS

INDUCTION


Day 1:

160 mg*
>

Day 15:

80 mg

MAINTENANCE


Day 29:

40 mg

every week

or

80 mg

every other week

Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

*Given in 1 day or split over 2 consecutive days.

Indication: HULIO is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.1

  • Crohn’s Disease
  • Ulcerative Colitis

ADULTS

INDUCTION


Day 1:

160 mg*
>

Day 15:

80 mg

MAINTENANCE


Day 29:

40 mg

every other week


CHILDREN ≥6 years

17 kg (37 lbs) to <40 kg (88 lbs)

Day 1:

80 mg
>

Day 15:

40 mg

Day 29:

20 mg

every other week

≥40 kg (88 lbs)

Day 1:

160 mg*
>

Day 15:

80 mg

Day 29:

40 mg

every other week

Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

*Given in 1 day or split over 2 consecutive days.

Indication: HULIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.1

ADULTS

INDUCTION


Day 1:

160 mg*
>

Day 15:

80 mg

MAINTENANCE


Day 29:

40 mg

every other week

Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

Discontinue HULIO in adult patients without evidence of clinical remission by 8 weeks (Day 57) of therapy.

*Given in 1 day or split over 2 consecutive days.

Indication: HULIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.1

Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.1

  • Uveitis

ADULTS

INDUCTION


Day 1:

80 mg

MAINTENANCE


Day 8:

40 mg

every other week

Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

Indication: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.1

  • Rheumatology
    • Rheumatoid Arthritis

      MAINTENANCE


      ADULTS

      40 mg

      every other week

      Indication: HULIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HULIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).1

    • Psoriatic Arthritis

      MAINTENANCE


      ADULTS

      40 mg

      every other week

      Indication: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.1

    • Ankylosing Spondylitis

      MAINTENANCE


      ADULTS

      40 mg

      every other week

      Indication: HULIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.1

    • Juvenile Idiopathic Arthritis

      MAINTENANCE


      CHILDREN ≥2 years

      15 kg (33 lbs) to
      <30 kg (66 lbs)

      20 mg

      every other week

      ≥30 kg (66 lbs)

      40 mg

      every other week

      There is no dosage form for HULIO that allows weight-based dosing for pediatric patients below 15 kg.

      Adalimumab products have not been studied in patients with polyarticular juvenile idiopathic arthritis less than 2 years of age or in patients with a weight below 10 kg.

      Indication: HULIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HULIO can be used alone or in combination with methotrexate.1

    • Uveitis

      INDUCTION


      ADULTS

      Day 1:

      80 mg

      MAINTENANCE


      ADULTS

      Day 8:

      40 mg

      every other week

      Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

      Indication: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.1

  • Dermatology
    • Psoriatic Arthritis

      MAINTENANCE


      ADULTS

      40 mg

      every other week

      Indication: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.1

    • Plaque Psoriasis

      INDUCTION


      ADULTS

      Day 1:

      80 mg

      MAINTENANCE


      ADULTS

      Day 8:

      40 mg

      every other week

      Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

      Indication: HULIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HULIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.1

    • Hidradenitis Suppurativa

      INDUCTION


      ADULTS

      Day 1:

      160 mg*

      Day 15:

      80 mg

      MAINTENANCE


      ADULTS

      Day 29:

      40 mg

      every week

      or

      80 mg

      every other week

      Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

      *Given in 1 day or split over 2 consecutive days.

      Indication: HULIO is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.1

  • Gastroenterology
    • Crohn’s Disease

      INDUCTION


      ADULTS

      Day 1:

      160 mg*

      Day 15:

      80 mg
      CHILDREN ≥6 years

      17 kg (37 lbs) to
      <40 kg (88 lbs)

      Day 1:

      80 mg

      Day 15:

      40 mg

      ≥40 kg (88 lbs)

      Day 1:

      160 mg*

      Day 15:

      80 mg

      MAINTENANCE


      ADULTS

      Day 29:

      40 mg

      every other week

      CHILDREN ≥6 years

      17 kg (37 lbs) to
      <40 kg (88 lbs)

      Day 29:

      20 mg

      every other week

      ≥40 kg (88 lbs)

      Day 29:

      40 mg

      every other week

      Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

      *Given in 1 day or split over 2 consecutive days.

      Indication: HULIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.1

    • Ulcerative Colitis

      INDUCTION


      ADULTS

      Day 1:

      160 mg*

      Day 15:

      80 mg

      MAINTENANCE


      ADULTS

      Day 29:

      40 mg

      every other week

      Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

      Discontinue HULIO in adult patients without evidence of clinical remission by 8 weeks (Day 57) of therapy.

      *Given in 1 day or split over 2 consecutive days.

      Indication: HULIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.1

      Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.1

  • Ophthalmology
    • Uveitis

      INDUCTION


      ADULTS

      Day 1:

      80 mg

      MAINTENANCE


      ADULTS

      Day 8:

      40 mg

      every other week

      Current adalimumab patients do not need to repeat induction dose—initiate HULIO as next scheduled dose.

      Indication: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.1

References: 1. HULIO. Prescribing information. Biocon Biologics Inc; 2023. 2. HUMIRA. Prescribing information. AbbVie Inc; 2021. 

 Open ISI Tray 

Important Safety Information and Indications

SERIOUS INFECTIONS

Patients treated with adalimumab products including HULIO® (adalimumab-fkjp) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue HULIO if a patient develops a serious infection or sepsis.

Discontinue HULIO if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HULIO use and during therapy. Initiate treatment for latent TB prior to HULIO use.
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with HULIO prior to initiating therapy in patients:

1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) with a history of opportunistic infection, 4) who resided in or traveled in regions where mycoses are endemic, 5) with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HULIO, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  • Do not start HULIO during an active infection, including localized infections.
  • Patients older than 65 years, patients with comorbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
  • If an infection develops, monitor carefully and initiate appropriate therapy.
  • Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of HULIO with other biologic DMARDs (e.g., anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.

  • Consider the risks and benefits of HULIO treatment prior to initiating or continuing therapy in a patient with known malignancy.
  • In clinical trials of some TNF blockers, including adalimumab products, more cases of malignancies were observed among TNF-blocker-treated patients compared to control patients.
  • Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or PUVA therapy, for the presence of NMSC prior to and during treatment with HULIO.
  • In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general US population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.
  • Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.

HYPERSENSITIVITY

  • Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If a serious allergic reaction occurs, stop HULIO and institute appropriate therapy.

HEPATITIS B VIRUS REACTIVATION

  • Use of TNF blockers, including HULIO, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
  • Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.
  • Exercise caution in patients who are carriers of HBV and monitor them during and after HULIO treatment.
  • Discontinue HULIO and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming HULIO after HBV treatment.

NEUROLOGIC REACTIONS

  • TNF blockers, including adalimumab products, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome.
  • Exercise caution when considering HULIO for patients with these disorders; discontinuation of HULIO should be considered if any of these disorders develop.
  • There is a known association between intermediate uveitis and central demyelinating disorders.

HEMATOLOGIC REACTIONS

  • Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.
  • Consider stopping HULIO if significant hematologic abnormalities occur.

CONGESTIVE HEART FAILURE

  • Worsening and new-onset congestive heart failure (CHF) have been reported with TNF blockers. Cases of worsening CHF have been observed with adalimumab products; exercise caution and monitor carefully.

AUTOIMMUNITY

  • Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

  • Patients on HULIO should not receive live vaccines.
  • Pediatric patients, if possible, should be brought up to date with all immunizations before initiating HULIO therapy.
  • Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in utero exposed infant. The safety of administering live or live- attenuated vaccines in infants exposed to HULIO in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS

  • The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache, and rash.

INDICATIONS

  • Rheumatoid Arthritis: HULIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HULIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
  • Juvenile Idiopathic Arthritis: HULIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HULIO can be used alone or in combination with methotrexate.
  • Psoriatic Arthritis: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.
  • Ankylosing Spondylitis: HULIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
  • Crohn’s Disease: HULIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
  • Ulcerative Colitis: HULIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
    Limitations of Use:
    The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.
  • Plaque Psoriasis: HULIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HULIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
  • Hidradenitis Suppurativa: HULIO is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.
  • Uveitis: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Please see accompanying Full Prescribing Information including BOXED WARNING.

Important Safety Information and Indications

SERIOUS INFECTIONS

Patients treated with adalimumab products including HULIO® (adalimumab-fkjp) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue HULIO if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HULIO use and during therapy. Initiate treatment for latent TB prior to HULIO use.
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with HULIO prior to initiating therapy in patients:

1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) with a history of opportunistic infection, 4) who resided in or traveled in regions where mycoses are endemic, 5) with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HULIO, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  • Do not start HULIO during an active infection, including localized infections.
  • Patients older than 65 years, patients with comorbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
  • If an infection develops, monitor carefully and initiate appropriate therapy.
  • Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of HULIO with other biologic DMARDs (e.g., anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.

  • Consider the risks and benefits of HULIO treatment prior to initiating or continuing therapy in a patient with known malignancy.
  • In clinical trials of some TNF blockers, including adalimumab products, more cases of malignancies were observed among TNF-blocker-treated patients compared to control patients.
  • Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or PUVA therapy, for the presence of NMSC prior to and during treatment with HULIO.
  • In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general US population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.
  • Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.

HYPERSENSITIVITY

  • Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If a serious allergic reaction occurs, stop HULIO and institute appropriate therapy.

HEPATITIS B VIRUS REACTIVATION

  • Use of TNF blockers, including HULIO, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
  • Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.
  • Exercise caution in patients who are carriers of HBV and monitor them during and after HULIO treatment.
  • Discontinue HULIO and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming HULIO after HBV treatment.

NEUROLOGIC REACTIONS

  • TNF blockers, including adalimumab products, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome.
  • Exercise caution when considering HULIO for patients with these disorders; discontinuation of HULIO should be considered if any of these disorders develop.
  • There is a known association between intermediate uveitis and central demyelinating disorders.

HEMATOLOGIC REACTIONS

  • Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.
  • Consider stopping HULIO if significant hematologic abnormalities occur.

CONGESTIVE HEART FAILURE

  • Worsening and new-onset congestive heart failure (CHF) have been reported with TNF blockers. Cases of worsening CHF have been observed with adalimumab products; exercise caution and monitor carefully.

AUTOIMMUNITY

  • Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

  • Patients on HULIO should not receive live vaccines.
  • Pediatric patients, if possible, should be brought up to date with all immunizations before initiating HULIO therapy.
  • Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in utero exposed infant. The safety of administering live or live- attenuated vaccines in infants exposed to HULIO in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS

  • The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache, and rash.

INDICATIONS

  • Rheumatoid Arthritis: HULIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HULIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
  • Juvenile Idiopathic Arthritis: HULIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HULIO can be used alone or in combination with methotrexate.
  • Psoriatic Arthritis: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.
  • Ankylosing Spondylitis: HULIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
  • Crohn’s Disease: HULIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
  • Ulcerative Colitis: HULIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
    Limitations of Use:
    The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.
  • Plaque Psoriasis: HULIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HULIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
  • Hidradenitis Suppurativa: HULIO is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.
  • Uveitis: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Please see accompanying Full Prescribing Information including BOXED WARNING.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm